Published in Pharma Law Weekly, December 26th, 2006
The SAB, which includes physicians, clinicians, and biotechnology industry professionals, will provide counsel on a broad range of scientific and product development issues.
"We are extremely pleased to have this distinguished group of leading scientists and physicians join Cardium's inaugural scientific advisory board," stated Christopher J. Reinhard, Cardium's chairman and chief executive officer. "Their deep knowledge and experience will be important as we look to advance our product candidates currently in development toward...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.